Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Selected Inclusion Criteria:~1. Adult male and female, HIV-1-infected patients 18 years old and older.~2. Body mass index (BMI) 18 to \< 35 kg/m2.~3. Antiretroviral treatment-naïve. Treatment-naïve is defined as:~   * No prior nonnucleoside reverse transcriptase inhibitor, other than in women who received a single dose of perinatal nevirapine who have no K103 viral mutation.~  * No prior CCR5 antagonist therapy.~  * No more than 10 days of any other prior antiretroviral therapy.~4. HIV-1 CCR5-tropic-only virus.~5. Plasma HIV-1 RNA level \>/=1,000 copies/mL at first Screening.~6. CD4 cell count \>/=250 cells/mm3 at first Screening.~Selected Exclusion Criteria:~1. Presence of CXCR4- or dual/mixed-tropic HIV-1 virus.~2. Presence of primary resistance mutations or phenotypic resistance to TDF, FTC, or EFV and/or mutations associated with multidrug nucleoside/nucleotide resistance.~3. An active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial).~4. Any historical CD4 count \< 200 cells/mm3.~5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value Grade \> 2 or total bilirubin greater than the upper limit of normal (ULN).~6. History of HIV-2, hepatitis B and/or C, cirrhosis of the liver, or any known active or chronic liver disease. Hepatitis B vaccinated patients are eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CVC 100 mg + Truvada (Type: EXPERIMENTAL): None
- CVC 200 mg + Truvada (Type: EXPERIMENTAL): None
- Sustiva + Truvada (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).